HCM vs. INSM, AXSM, CRNX, PBH, RARE, PRGO, ALKS, BHVN, SMMT, and IDYA Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Insmed (INSM), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Alkermes (ALKS), Biohaven (BHVN), Summit Therapeutics (SMMT), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
Insmed (NASDAQ:INSM ) and HUTCHMED (NASDAQ:HCM ) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
Insmed received 193 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.60% of users gave HUTCHMED an outperform vote while only 64.79% of users gave Insmed an outperform vote.
Insmed has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
HUTCHMED has a net margin of 0.00% compared to HUTCHMED's net margin of -236.74%.
Insmed presently has a consensus target price of $44.71, indicating a potential upside of 80.52%. HUTCHMED has a consensus target price of $29.70, indicating a potential upside of 47.25%. Given HUTCHMED's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insmed is more favorable than HUTCHMED.
HUTCHMED has higher revenue and earnings than Insmed.
8.8% of HUTCHMED shares are owned by institutional investors. 4.6% of Insmed shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Insmed had 23 more articles in the media than HUTCHMED. MarketBeat recorded 31 mentions for Insmed and 8 mentions for HUTCHMED. Insmed's average media sentiment score of 0.58 beat HUTCHMED's score of 0.42 indicating that HUTCHMED is being referred to more favorably in the news media.
Summary Insmed beats HUTCHMED on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
HUTCHMED Competitors List
Related Companies and Tools
